Explore Our Publications
Entrada’s commitment to publications & transparency
Entrada is committed to publishing the results of our sponsored research in a transparent, scientifically accurate, and timely manner. Entrada will apply high ethical standards to our publications and presentations and will adhere to recognized industry guidance such as International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals and International Society for Medical Publication Professionals (ISMPP) Good Publication Practice for Communicating Company Sponsored Medical Research.
Upcoming Presentations
-
Clinical Trial of ENTR-601-44, an Endosomal Escape Vehicle (EEV™)-Oligonucleotide Conjugate for the Treatment of Duchenne Muscular Dystrophy
- By: Mahasweta Girgenrath, PhD, Vice President, Neuromuscular, Entrada Therapeutics
- At: 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
- On: May 14, 2025
May 14, 2025 -
Exon 45 Skipping, Dystrophin Production, and Functional Improvement With ENTR-601-45 in Preclinical Models of Duchenne Muscular Dystrophy
- By: Xiang Li, PhD, Director, Discovery Research, Entrada Therapeutics
- At: 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
- On: May 15, 2025
May 15, 2025 -
The Endosomal Escape Vehicle Platform Safely and Effectively Delivers Oligonucleotide Therapeutics to Skeletal and Cardiac Muscle Tissue for the potential treatment of Duchenne Muscular Dystrophy
- By: Leo Ziqing Qian, PhD, Co-Founder & Vice President, Discovery Research, Entrada Therapeutics
- At: TIDES USA
- On: May 22, 2025
May 22, 2025
Past Presentations
-
The Endosomal Escape Vehicle Platform Safely & Effectively Delivers Oligonucleotide Therapeutics to Skeletal and Cardiac Muscle Tissue for the Potential Treatment of Duchenne Muscular Dystrophy
- By: Matt Streeter, PhD, Sr. Scientist, Discovery Chemistry, Entrada Therapeutics
- At: 2nd Annual Peptide-Based Therapeutics Summit
- On: April 3, 2025
DownloadApril 3, 2025 -
Endosomal Escape Vehicle (EEV™)-Conjugated Phosphorodiamidate Morpholino Oligomer (PMO) Therapeutics For The Treatment Of Duchenne Muscular Dystrophy
- By: Katie Miller, PhD, Scientist II, Discovery Chemistry, Entrada Therapeutics
- At: 4th Annual Novel Conjugates Summit
- On: March 26, 2025
DownloadMarch 26, 2025 -
Therapeutic Potential of ENTR-601-44, an Endosomal Escape Vehicle (EEV™)-Oligonucleotide Conjugate for the Treatment of Exon 44 Skip Amenable Duchenne Muscular Dystrophy
- By: Mahasweta Girgenrath, PhD, Vice President, Neuromuscular, Entrada Therapeutics
- At: 2025 Solve FSHD Meeting
- On: March 26, 2025
DownloadMarch 26, 2025 -
Results of a Phase 1 Study to Assess the Safety, Pharmacokinetics, and Exon 44 Skipping of ENTR-601-44 in Healthy Human Volunteers
- By: Natarajan Sethuraman, PhD, President of Research and Development, Entrada Therapeutics
- At: 2025 MDA Clinical & Scientific Conference
- On: March 16, 2025
DownloadMarch 16, 2025 -
Exon 45 Skipping, Dystrophin Production, and Functional Improvement with ENTR-601-45 in Preclinical Models of Duchenne Muscular Dystrophy
- By: Mahasweta Girgenrath, PhD, Vice President, Neuromuscular, Entrada Therapeutics
- At: 2025 MDA Clinical & Scientific Conference
- On: March 16, 2025
DownloadMarch 16, 2025 -
Exon 45 Skipping and Dystrophin Production with ENTR-601-45 in Preclinical Models of Duchenne Muscular Dystrophy
- By: Amy Hicks, PhD, Associate Director, Neuromuscular, Entrada Therapeutics
- At: 2024 ASGCT Breakthroughs in Muscular Dystrophy
- On: November 19, 2024
DownloadNovember 19, 2024